Article
A novel AR molecular glue degrader via bivalent engagement of the N-terminal domain and RNF213–UBE2J2 complex
2026-07-16
Abstract excerpt
Targeted protein degradation enables the elimination of disease-relevant proteins through induced proximity between E3 ligases and substrates. Current androgen receptor (AR) therapies act via the ligand-binding domain (LBD) but fail against constitutively active LBD mutants or splice variants such as AR-V7. Here, we identify GZL626, a small-molecule degrader that induces proteasome-dependent degradation of both fu...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- bf5f4f03-0b0c-5402-a7fb-f501ebc0a78e
- DOI
- 10.64898/2026.07.14.738453
